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Introduction: Colorectal cancer (CRC) is one of the most widespread 
Cancers across the world. Notwithstanding the diagnoses and treatments 
developed over the past four decades, patients' survival rate has improved 
moderately; and yet, it still has a 5-year survival rate of less than 50%.  
In this study, hypermethylation of the NDRG4 gene was evaluated as a 
biomarker in CRC screening.  
Materials and Methods: 70 samples were examined in this case-control 
study (45 CRC patients versus 25 healthy controls) totally, and Methylation-
Specific PCR (Polymerase Chain Reaction) technique was used to investigate 
the NDRG4 methylation situation in plasma samples.  
Results: The mean age in the control group and CRC patients was 58.4±3.4 
years and 64.6±4.4 years, respectively. The male to female ratio in the 
control group and CRC patients was 1.5:1 and 1.1:1, respectively. 
Gastrointestinal disease history was positive in 12% and 33% of patients in 
the control group and CRC patients. In this study, NDRG4 gene 
hypermethylation was observed in 53.3% of patients, while it was shown in 
only 23.3% of healthy controls. 
Conclusion: The results showed that NDRG4 could be a prognostic 
biomarker in CRC diagnosis and screen as a noninvasive blood-based 
biomarker. 
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     Colorectal cancer (CRC) is considered as 
the third of the most common and fatal 
cancers in the world [1]. This cancer 
originates from the internal mucosa of the 
colon [2]. Most colon and rectal cancer 
tumors grow slowly and may not develop 
symptoms until they reach an enormous size 
and eventually become dangerous [3]. CRC 
originates from an adenomatous polyp or  
 
flat tissue dysplasia with a background of 
inflammatory bowel disease. High-grade 
dysplasia in the backbone of adenomatosis 
most likely results in invasive 
adenocarcinoma. The invasion of the lamina 
propria and mucosa layer rarely results in 
metastasis to the lymph nodes. The factor 
that leads to invasive adenocarcinoma is the 
involvement of the submucosal layer [4, 5]. 
Colon cancer is currently the most common 
cancer recognized across the world. 
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Although significant improvement in 
diagnoses and treatments occured over the 
past four decades, and the survival rate of 
patients has improved to some extent,  it 
still has a 5-year survival rate of less than 
50%. The most important prognostic factor 
in colorectal cancer is the stage of the 
disease at diagnosis, and it is said to be the 
most effective way to improve the 
prognosis of the disease early on in its 
progression. Unfortunately, symptomatic 
colorectal cancer presents the symptoms 
when the disease has reached its advanced 
stages; hence, early detection and 
population screening for at-risk or early-
stage patients is an effective way to reduce 
the incidence of the disease [6, 7]. 
The NDRG4 gene is a member of the 
NDRG gene family, including the other 
three NDRG1-3 genes, with approximately 
60% homology between the products. 
NDRG4 is a candidate gene with a tumor 
suppressor role located in the 16q21-q22.3 
chromosome region. Studies of mouse 
embryos have shown that under conditions 
of ventricular hypoplasia, NDRG4 gene 
expression is reduced, indicating the role of 
this gene in cell growth and proliferation. 
NDRG4 gene is hypermethylated in 
colorectal cancer. This methylation change 
suggests that this gene may be involved in 
the pathway of carcinogenesis and the 
development of colorectal cancer. A large 
number of studies have shown that the 
NDRG4 gene plays a role in tumor 
suppression in a variety of human cancers is 
increasing. Given the previously shown role 
of the NDRG2 gene in tumor suppression of 
colorectal cancer, and as NDGR4 has more 
than 60% similarity to the amino acid 
sequence of NGDR2, evidence can be 
drawn for the role of NDRG4 gene in tumor 
suppression of colorectal cancer [8, 9]. 
In the present study, considering the 
importance of early detection of colorectal 
cancer, the NDRG4 gene was selected as to 
investigate the promoter methylation 
changes. The promoter methylation of this 
gene was evaluated qualitatively by means 
of Methylation-Specific Polymerase Chain 
Reaction (MSPCR) in plasma samples of 
patients with colorectal adenocarcinoma 
compared to the control group.  
 
2. Materials and Methods 
2.1. Study Design and Patients:  
     In this study, 45 patients with colorectal 
cancer and 25    healthy controls (with no 
evidence of disease) were enrolled. After 
getting a written informed consent from the 
participants, a questionnaire was filled by 
every participant to obtain their 
demographic data, as well as their disease 
signs and conditions. Five milliliters of 
peripheral blood samples were collected 
from patients. 
 
2.2. DNA Extraction:  
     DNA isolation performed in 500 μL 
plasma using the QIAamp DNA Blood Mini 
kit (Qiagen-Germany) and stored at -20°C.  
 
2.3. Bisulfite Treatment:  
     As mentioned earlier, before performing 
MSP, DNA was treated with bisulfite to 
convert unmethylated cytosine to uracil 
[10]. 
 
2.4. MS-PCR:  
     Methylation-Specific PCR (MSP) was 
carried out to specify the methylation status 
of the gene. The NDRG4 gene primer 
sequences for the methylated and 











NDRG4 PCR product size was 142 bp. 
Each PCR reaction mix included a total 
volume of 20 μl containing 10 μl hot start 
Taq Master Mix, 1 μM concentration of 
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each primer, 1 μl DMSO, 3 μl bisulfite- 
modified DNA and 5 μl RNase free water. 
The PCR temperature program is shown in 
table 1. 
 
2.5. Gel Electrophoresis.  
     After PCR, a 3% agarose gel was used to 
manifest PCR products. 
Table 1. PCR temperature program. 
Stage Temperature Time Cycles 
Pre-incubation 94 °C 15 minutes 1 
Amplification 94 °C 1 minutes 35 
59 °C 40 seconds 
72 °C 40 seconds 
Final extension 72 °C 1 minutes 1 
 
2.6. Statistical Analysis:  
     Two tests, including Fisher’s exact test 
and χ2 test, were applied to investigate the 
statistical relationships between methylation 
situation of NDRG4 gene and pathological 
or demographical results and assess 
hypermethylation in patients. As the P 





     Seventy individuals in two groups of 
CRC patients and healthy controls were 
enrolled in this study. Demographic data 
was as follows: The mean age in the control 
group and CRC patients was 58.4±3.4 years 
and 64.6±4.4 years, respectively. The male 
to female ratio in the control group and 
CRC patients was 1.5:1 and 1.1:1, 
respectively. Gastrointestinal disease 
history was positive in 12% and 33% of 
patients in the control group and CRC 
patients. 
 
Status of Hypermethylation in Plasma 
Samples: 
      As shown in Table 2, 24 of 45 (53.3%) 
CRC patients and 6 of 25 (23.3%) healthy 
controls revealed hypermethylation in the 
NDRG4 gene. Gel electrophoresis result for 
the NDRG4 gene in 5 samples of CRC 
patients is shown in Figure 1.  As displayed 
in Figure 1, there were 45 patient samples. 
Patients 1 and 5 have both methylated and 
unmethylated PCR amplification, which is 
interpreted as methylated heterozygotes. 
Only patient 2 can be interpreted as a 
methylated homozygote. Patients 3 and 4 




Table 2. Methylation status of NDRG4 in study population. 
 
 
Group                                                     Controls                         CRC 
 Positive (Methylated)                          6 (23.3%)                     24 (53.3%) 
 Negative (Unmethylated)                   19 (76.8%)                    21 (43.2%) 
 Total                                                   25 (100%)                      45 (100%)  
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Figure 1. Gel electrophoresis result for NDRG4 gene. From the left, 100bp ladder, mP.C: positive methylated control, 
mN.C: M1-M5: patient samples with methylated primer. U1-U5: patient samples with unmethylated primer. PCR 
product: 142 bp. 
 
4. Discussion  
     Among the different screening methods 
for CRC, markers that are examined using 
blood samples, given the ease of sampling, 
non-invasiveness, and relative patient 
satisfaction (compared to a procedure such 
as colonoscopy), seem to be the most 
suitable for biomarker presentation. 
Different serum and plasma markers have 
been studied in CRC research. One of the 
most well-known and proven of these 
markers is the SEPT9 marker, which has 
been discussed in several studies as a 
diagnostic biomarker [11, 12]. For the 
current research, the SEPT9 biomarker in 
the form of Epi proColon® commercial 
kits, ColoVantage®, has been used as CRC 
diagnostic kits by assessing methylated 
SEPT9 gene [13]. Imperial et al.[14] studied 
stool DNA testing in CRC screening. In this 
study, NDRG4 and BMP3 
hypermethylation and fecal hemoglobin 
were examined. Based on the information 
obtained from this study, the rate of 
diagnosis of high-grade polyps and 
dysplasia using this panel was 62.9%. This 
study demonstrated that this method is 
suitable for population screening, given the 
non-invasive stool test [14]. 
There have been several studies that 
investigate the hypermethylation of the 
NDRG gene family; In the study of Liu et 
al.[15], the promoter methylation, mutations 
and genomic deletions of the NDRG2 gene 
were investigated in several cell lines from 
different cancers. The results of this study 
revealed that heterozygous deletion 
mutations, as well as promoter methylation 
of the NDRG2 gene, occur in a variety of 
cancers (including CRC) [15]. In the study 
of Melotte et al.[16], Methylation of the 
NDRG4 gene was evaluated in three CRC 
tissue samples, healthy colonic mucosal 
tissue and CRC cell lines using the MS-
PCR technique. The results of this study 
indicated that 86% of the tissue cancers, and 
70% of the cell lines showed 
hypermethylation in the NDRG4 gene. 
Furthermore, the expression of the NDRG4 
gene was significantly decreased in cancer 
samples compared to healthy tissue [16].  
The sample used in the present study was a 
blood plasma sample from patients; the 
most important reason for selecting a 
plasma sample was to find a non-invasive 
method for screening purposes. In recent 
years, tumor-associated cell-free DNA 
(cfDNA) in plasma and serum has been 
used as a non-invasive method for detecting 
cancers. This method is called liquid 
biopsy, which can detect genetic or 
epigenetic changes in cfDNA. In a study 
conducted by Ashoori et al.[17], epigenetic 
biomarker Bone Morphogenic Protein 3 for 
CRC screening was investigated. 75 percent 
of CRC patients showed hypermethylation 
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in the BMP3 gene in plasma samples. At the 
same time the percentage for the control 
group was only 30. In colonoscopy tissue 
biopsies, in 81.6% of CRC patients, BMP3 
hypermethylation was showed. Specificity 
and sensitivity of this gene in CRC 
diagnosis were about 76% and 66%, 
respectively. [17]. 
In the present study, the mean age of CRC 
patients was 64.4 years, while in the control 
group, the mean age was 58.40 years. CRC 
has a direct relationship with age, and if age 
is considered as a risk factor, the risk 
increases with age. According to the Cancer 
Research Organization, the incidence of 
CRC is the most rapidly increasing age 
range of 50 to 54, reaching its highest level 
in people over the age of 75; 44% of the 
diagnosed CRC cases are patients aged 75 
years and over; 54% of the patients in the 
present study were between the ages of 51 
and 70, which is consistent with the Cancer 
Research Organization statistics. 
 
5. Conclusion  
     In conclusion, the results of this study 
showed that NDRG4 can be a promising 
biomarker for the detection of 
adenocarcinomas of the colon and rectal 
and can be used as a noninvasive blood-
based biomarker. Future studies can help 
achieve more promising results by 
investigating the relationship between the 
family record and environmental factors 
with epigenetic changes, especially gene 
methylation in colorectal cancer. 
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